Neil Graham
Direktor/Vorstandsmitglied bei ASLAN PHARMACEUTICALS LIMITED
Vermögen: - $ am 31.05.2024
Aktive Positionen von Neil Graham
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ASLAN PHARMACEUTICALS LIMITED | Direktor/Vorstandsmitglied | 18.02.2021 | - |
Independent Dir/Board Member | 18.02.2021 | - | |
ZURA BIO LIMITED | Direktor/Vorstandsmitglied | 01.03.2023 | - |
Independent Dir/Board Member | 01.03.2023 | - | |
ALLAKOS INC. | Direktor/Vorstandsmitglied | 30.08.2023 | - |
Independent Dir/Board Member | 30.08.2023 | - | |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | Direktor/Vorstandsmitglied | - | - |
Independent Dir/Board Member | - | - |
Karriereverlauf von Neil Graham
Ehemalige bekannte Positionen von Neil Graham
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SYNTARA LIMITED | Direktor/Vorstandsmitglied | 04.05.2020 | 03.10.2023 |
Independent Dir/Board Member | 04.05.2020 | 03.10.2023 | |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | 13.01.2021 | 18.07.2022 |
REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2009 | 01.01.2020 |
VERTEX, INC. | Corporate Officer/Principal | 01.04.2007 | 01.11.2009 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01.06.2005 | 01.02.2007 |
░░░ ░░░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░ ░░░░░░░░░ ░░░░░░ ░░ ░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von Neil Graham
University of Adelaide | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Australien | 3 |
Singapur | 3 |
Operativ
Corporate Officer/Principal | 6 |
Director/Board Member | 5 |
Independent Dir/Board Member | 5 |
Sektoral
Health Technology | 12 |
Consumer Services | 3 |
Technology Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 8 |
---|---|
REGENERON PHARMACEUTICALS, INC. | Health Technology |
XTL BIOPHARMACEUTICALS LTD. | Health Technology |
SYNTARA LIMITED | Health Technology |
EVELO BIOSCIENCES, INC. | Health Technology |
VERTEX, INC. | Technology Services |
ASLAN PHARMACEUTICALS LIMITED | Health Technology |
ZURA BIO LIMITED | Health Technology |
ALLAKOS INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | Health Technology |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | Health Technology |
Glaxo Wellcome Plc | Health Technology |
- Börse
- Insiders
- Neil Graham
- Erfahrung